Trials / Completed
CompletedNCT02681991
Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- Daewon Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Renamezin Capsule (an oral adsorbent) lowers indoxyl sulfate levels in patient with chronic renal failure. 120 patients with chronic renal failure(baseline serum creatinine:1.5-5.0mg/dl). Renamezin is administered 6.0mg/day. The treatment period is 2 months. The change in serum indoxyl sulfate will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Renamezin capsule |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2016-02-15
- Last updated
- 2017-07-06
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02681991. Inclusion in this directory is not an endorsement.